# Simpler Grants.gov #RFA-MH-27-150

NIH seeks a clinical-trials network for rapid-acting psychotropic interventions

**Buyer:** National Institutes of Health
**Posted:** November 12, 2026
**Respond By:** June 10, 2027
**Identifier:** RFA-MH-27-150
**NAICS:** 541715, 541720, 621112, 621330, 621420, 622210, 623220

The National Institutes of Health is seeking applications to build a clinical-trials network for rapid-acting psychotropic interventions.
- **Government buyer:** U.S. Department of Health and Human Services (HHS), National Institutes of Health (NIH), led by the National Institute of Mental Health (NIMH), with the National Institute on Drug Abuse (NIDA) participating.
- **Requested work:** Establish and operate the Rapid-Acting Psychotropic Interventional Drugs Clinical Trials Network (RAPIDs-CTN), including a Data Coordinating Center and a network of federated clinical sites.
  - Conduct adaptive, multisite pragmatic trials in real-world care settings to evaluate effectiveness, safety, implementation, sustainability, delivery models, costs, monitoring, and retreatment.
- **Treatments in scope:** Ketamine, esketamine, and emerging agents including psilocybin and MDMA. No drug manufacturers or commercial vendors are named.
- **Structure and funding:** A milestone-driven UM1 cooperative agreement with two stages: network establishment and pilot studies in Years 1–2, then full-scale trial execution in Years 3–5. The notice anticipates three awards and lists $12 million in total program funding, including up to $10 million from NIMH and up to $2 million from NIDA.
- **Notable requirements:** Use NIMH-supported Common Data Elements, create standardized data and harmonization workflows, and prepare data for deposition in the NIMH Data Archive. The work also includes centralized coordination, biostatistics, data management, and safety monitoring.

### Description

This funding opportunity supports establishing a Rapid-Acting Psychotropic Interventional Drugs–Clinical Trials Network (RAPIDs-CTN) to generate real-world evidence about the safe and effective implementation of RAPIDs in routine clinical practice. Projects use a milestone-driven UM1 Cooperative Agreement with Stage 1 (Years 1–2) for network establishment and pilot studies, followed by Stage 2 (Years 3–5) for full-scale pragmatic trials. It is intended for large-scale, coordinated network projects. The opportunity lists expected project funding of $12,000,000 and three expected awards.

[View original listing](https://simpler.grants.gov/opportunity/363875)